Los Angeles Capital Management’s Ocular Therapeutix OCUL Stock Holding History

Los Angeles Capital Management’s Portfolio OCUL Stock Details OCUL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$3.61K	Hold	426	–	–	﹤0.01%	2203
2025 Q4	$5.04K	Buy	+426	New	+$5.17K	﹤0.01%	2281
2022 Q4	–	Sell	-275,984	Closed	-$1.15M	–	1250
2022 Q3	$1.15M	Hold	275,984	–	–	0.01%	649
2022 Q2	$1.11M	Sell	275,984 -74,304	-21%	-$281K	0.01%	686
2022 Q1	$1.73M	Buy	+350,288	New	+$1.94M	0.01%	579
2021 Q2	–	Sell	-13,285	Closed	-$218K	–	1637
2021 Q1	$218K	Sell	13,285 -125	-0.9%	-$2.41K	﹤0.01%	1517
2020 Q4	$278K	Buy	+13,410	New	+$199K	﹤0.01%	1396

Other funds holding OCUL

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Summer Road West Palm Beach, Florida $142M AUM 43.61% 1-Year Est. Return

VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Los Angeles Capital Management's OCUL Position: Q1 2026 in Review

Los Angeles Capital Management held its Ocular Therapeutix (OCUL) position steady in Q1 2026 at 426 shares worth $3.61K. The position accounts for ﹤0.01% of the portfolio, ranked #2203.

Los Angeles Capital Management first reported a position in OCUL in Q4 2020 and has held it in 7 quarters since. The position peaked at $1.73M in Q1 2022. 269 funds tracked by Wall St. Rank hold OCUL as of Q1 2026.

Los Angeles Capital Management held 426 shares of Ocular Therapeutix worth $3.61K as of Q1 2026.
Los Angeles Capital Management left its Ocular Therapeutix share count unchanged in Q1 2026.
Ocular Therapeutix made up ﹤0.01% of Los Angeles Capital Management's portfolio in Q1 2026, its #2203 holding.
Los Angeles Capital Management first reported a position in Ocular Therapeutix in Q4 2020 and has held it in 7 quarters since.
Los Angeles Capital Management's Ocular Therapeutix position peaked at $1.73M in Q1 2022.
269 funds tracked by Wall St. Rank held Ocular Therapeutix as of Q1 2026.

Based on Los Angeles Capital Management's 13F filing for Q1 2026, filed 8 May 2026.